no longer on X (former Twitter). Reach me though: linkedin.com/in/oliver-prof-… or EMail: olliver@pfaar.org

For experts and stakeholders in AIT-research: EAACI Task-Force Position Paper on 'Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma' Read/Enjoy/Share. Best, Oliver pubmed.ncbi.nlm.nih.gov/3744…

Very recently published in WAO from our US- and EU-expert network: Comparison of allergen immunotherapy practice patterns in inhalant allergies in the US and Europe: Similarities and differences 2023: Unmet needs of AIT! Read/Enjoy/Share. Thanks, Oliver pubmed.ncbi.nlm.nih.gov/3725…

EAACI congress 2023 …so great to meet both KOLs and friends again!

On my way to Hamburg, Germany: Annual EAACI congress 2023: excited to meet so many colleagues and friends again. 4 days long !!! Find me in the programme: great to have you in the rooms or remote. Oliver

Berlin, 24.Mai :  16. Runder Tisch Allergologie  Wichtige berufspolitische Akzente mit gesundheitspolitischen Sprecher*innen des Deutschen Bundestages, GKV-Spitzenverbänden und Industrie: klarer Auftrag: PRO Allergologie und AIT !!!

Just published from our group: read/enjoy/share. Thank you, Oliver "Improvement of daily allergy control by sublingual immunotherapy: A MASK-air® study" (via #pubmedontap) ncbi.nlm.nih.gov/pubmed/3707…

Open Access: Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies. First and corresponding author: Oliver Pfaar Read the article here: doi.org/10.1111/all.15723 The understanding of adherence or persistence to allergen immunotherapy (AIT) is hampered by a lack of specific guidance on appropriate clinical trial design. Pfaar et al. conducted a comprehensive review of current evidence and developed a checklist to enhance the design and reporting of trials evaluating adherence or persistence to AIT. The APAIT checklist is novel and highlights an important issue in the allergy field. Read more articles published in #Allergy on allergen #immunotherapy here: journalallergy.com/Allergen-… #Allergy_journal @OPfaar

für Patient*innen mit einer schweren Form der chronischen Nasennebenhöhlenentzündung mit Polypen (#CRSwNP): nehmen Sie gerne gleich mit uns Kontakt auf:

Tel.: 06421 58 66933
EMail: allergiestudien.mr@uk-gm.de

Wir freuen uns auf Ihre Kontaktaufnahme👍!
Prof.Pfaar & Team

published (27 Mar 2023) & open access from our group: "Adherence and persistence in allergen immunotherapy (APAIT): a reporting checklist for retrospective studies" onlinelibrary.wiley.com/doi/…

jetzt online: "Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antikörpern (Biologika)" >> S2k-LL nach AWMF-Regelwerk samt Dokumentationsbogen und Evidenztabellen link.springer.com/content/pd…

STERN Ärzteliste „Allergien“ 2023 stern.de/siegel/aerzte/aller…

TV-Bericht über CRSwNP und Biologika: Nicht nur für Patienten interessant (sondern auch für Eintracht-Fans😀): youtube.com/watch?v=gQUhVW10…

Important reading: published today: AIT 111 years (part-2): also free access to all articles via Pubmed. dustri.com/nc/de/deutschspra…

Watch this message from @OPfaar - EAACI Congress Ambassador. Join us in Hamburg for the #EAACICongress2023 , an event that will offer the latest scientific breakthroughs, networking opportunities and countless possibilities to transform healthcare. ➡️ow.ly/jRvN50MZ2xg

Live from Dresden: AG Allergologie (DG HNO-KHC): meeting friends and top-experts in Rhinology

für meine Patientinnen und Patienten: bitte Termin vormerken ! DigiPat '23: TYP-2-Entzündungen, Asthma, Allergie auf Zahnmaterialien, Pollenallergie, Allergien auf Tierhaare, Anaphylaxie mein-allergie-portal.com/ima…

Allergen immunotherapy (AIT): Interesting bibliometric analysis: 2002-2021: pubmed.ncbi.nlm.nih.gov/3661…